Radical New Concepts in Lipid Management

2013 United States Cholesterol Guidelines vs ESC/EAS Guidelines for the Management of Dyslipidemias

Statin Therapy

ESC Categories of Individuals at High Risk

ESC Recommendations for Patients at Very High Risk

Randomized Controlled Studies Failing to Show Evidence of Further Reduced Risk When Adding a Nonstatin

IMPROVE-IT

On Statin Levels and Risk for CV Events

IMPROVE-IT Safety End Points

IMPROVE-IT

PCSK9 Monoclonal Antibodies

Baseline Characteristics Phase 3 Placebo-Controlled Trials

Post-hoc Adjudicated Cardiovascular TEAEs† Pooled From Phase 3 Placebo-Controlled Trials

ODYSSEY Long-term Safety Results

PCSK9 Loss-of-Function Mutations

TEAEs Comparable in Patients With 2 Consecutive LDL-C < 25 mg/dL

Safety Analysis Including All Data Collected Until Last Patient Visit at Week 52

PCSK9 Priority Patient Targets

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)